5-环丙基-2-噻唑胺 | 606092-87-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-环丙基-2-噻唑胺
• 英文名称: 5-cyclopropylthiazol-2-amine
• 英文别名: 5-cyclopropyl-1,3-thiazol-2-amine
• CAS: 606092-87-9
• 化学式: C₆H₈N₂S
• mdl: MFCD14706999
• 分子量: 140.209
• InChiKey: BXYAYILDSNLZLU-UHFFFAOYSA-N

物化性质

• 沸点：
  292.1±9.0 °C(Predicted)
• 密度：
  1.369±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  67.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  (S)-2-(3-bromophenyl)propanoic acid 、 5-环丙基-2-噻唑胺 在 草酰氯 、 N,N-二甲基甲酰胺 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 以78%的产率得到(S)-2-(3-bromophenyl)-N-(5-cyclopropylthiazol-2-yl)propanamide
  参考文献：
  名称：

  [EN] NOVEL THIAZOLE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
  [FR] NOUVEAUX DÉRIVÉS DE THIAZOLE ET SELS PHARMACEUTIQUEMENT ACCEPTABLES DE CEUX-CI

  摘要：

  本发明提供了一种新型噻唑衍生物或其药用可接受盐，并提供了其制备方法。根据本发明的噻唑衍生物或其药用可接受盐具有选择性抑制环依赖性激酶（CDK）的活性，因此可用作与CDK相关的各种疾病的预防或治疗剂。

  公开号：

  WO2020060112A1

文献信息

• [EN] NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION<br/>[FR] NOUVEAUX DÉRIVÉS D'AMINOPYRIDINE PRÉSENTANT UNE ACTION INHIBITRICE SÉLECTIVE DE L'AURORA A
  申请人：BANYU PHARMA CO LTD

  公开号：WO2010111056A1

  公开（公告）日：2010-09-30

  The present invention relates to a compound of Formula (I): wherein: R1 is H, -NHCOOR1a, C5-6 cycloalkyl, or phenyl; where the cycloalkyl and phenyl each independently may be substituted with one to three of the same or different substituents selected from R10; R1a is C1-3 alkyl which may be substituted with one to three of the same or different substituents selected from F and Cl; R2 is H, -COOH, -CH2 COOH, -COOR2a, or -CH2COOR2a; R2a is C1-2 alkyl, where the alkyl may be substituted with one to three of the same or different substituents selected from halogen atoms; R3 is H, C1-6 alkyl, where the alkyl may be substituted with one to three of the same or different substituents selected from R11; R10 is F, Cl, CF3, or C1-2 alkyl; R11 is halogen atom, hydroxy, or cyano; W is selected from: W2a is H, halogen atom, cyano, C1-2 alkyl, or C3-5 cycloalkyl, or a pharmaceutically acceptable salt or ester thereof.

  本发明涉及一种化合物，其化学式为（I）：其中：R1为H，-NHCOOR1a，C5-6环烷基或苯基；其中所述环烷基和苯基各自可以独立地被选自R10的一个至三个相同或不同取代基取代；R1a为C1-3烷基，可以被选自F和Cl的一个至三个相同或不同取代基取代；R2为H，-COOH，-CH2 COOH，-COOR2a或-CH2COOR2a；R2a为C1-2烷基，其中该烷基可以被选自卤原子的一个至三个相同或不同取代基取代；R3为H，C1-6烷基，其中该烷基可以被选自R11的一个至三个相同或不同取代基取代；R10为F，Cl，CF3或C1-2烷基；R11为卤原子，羟基或氰基；W选自：W2a为H，卤原子，氰基，C1-2烷基或C3-5环烷基，或其药学上可接受的盐或酯。
• Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents
  申请人：Pevarello Paolo

  公开号：US20050004120A1

  公开（公告）日：2005-01-06

  A method of modulating apoptosis or treating diseases associated with protein kinases by administering to a mammal in need thereof of an effective amount of 2-amino-1,3-thiazole derivatives represented by formula (I) or (II): where R, R 1 , R 2 and R 3 are as defined herein, or pharmaceutically acceptable salts thereof.

  通过向需要的哺乳动物投予有效量的由公式(I)或(II)表示的2-氨基-1,3-噻唑衍生物，或其药学上可接受的盐，来调节凋亡或治疗与蛋白激酶相关的疾病的方法：其中R、R1、R2和R3如本文所定义。
• 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents
  申请人：——

  公开号：US20030187040A1

  公开（公告）日：2003-10-02

  Compounds which are 2-ureido-1,3-thiazole derivatives of formula (I) wherein R is a halogen atom, a nitro group, an optionally substituted amino group or it is a group, optionally further substituted, selected from: i) straight or branched C1-C6 alkyl; ii) C3-C6 cycloalkyl; iii) aryl or arylalkyl with from 1 to 6 carbon atoms within the straight or branched alkyl chain; R1 is an optionally substituted group selected from: i) straight or branched C1-C6 alkyl; ii) 3 to 6 membered carbocycle or 5 to 7 membered heterocycle ring, iii) aryl or arylcarbonyl; iv) arylalkyl with from 1 to 6 carbon atoms within the straight or branched alkyl chain: R2 is hydrogen, a straight or branched C1-C4 alkyl or C2-C4 alkenyl or alkynyl group; or, taken together with the nitrogen atom to which they are bonded, R1 and R2 form a substituted or unsubstituted group selected from: i) an optionally benzocondensed or bridged 5 to 7 membered heterocycle; or ii) a 9 to 11 membered spiro-heterocyclic compound; or a pharmaceutically acceptable salt thereof; are useful for treating cell proliferative disorders associated with an altered cell dependent kinase activity.

  化合物是公式（I）的2-脲基-1,3-噻唑衍生物，其中R是卤素原子，硝基，可选择取代的氨基团或者是从以下选项中选择的可选择进一步取代的基团：i）直链或支链的C1-C6烷基；ii）C3-C6环烷基；iii）芳基或芳基烷基，在直链或支链烷基链中含有1至6个碳原子；R1是可选择取代的基团，选择自：i）直链或支链的C1-C6烷基；ii）3至6成员碳环或5至7成员杂环环，iii）芳基或芳基酰基；iv）芳基烷基，在直链或支链烷基链中含有1至6个碳原子；R2是氢，直链或支链的C1-C4烷基或C2-C4烯基或炔基；或者，与它们结合的氮原子一起，R1和R2形成一个选择自：i）可选择苯并或桥联的5至7成员杂环；或ii）9至11成员螺环杂环化合物；或其药用盐，用于治疗与改变的细胞依赖性激酶活性相关的细胞增殖异常。
• NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION
  申请人：Binch Hayley

  公开号：US20120015969A1

  公开（公告）日：2012-01-19

  The present invention relates to a compound of Formula (I): wherein: R 1 is H, —NHCOOR 1a , C 5-6 cycloalkyl, or phenyl; where the cycloalkyl and phenyl each independently may be substituted with one to three of the same or different substituents selected from R 10 ; R 1a is C 1-3 alkyl which may be substituted with one to three of the same or different substituents selected from F and Cl; R 2 is H, —COOH, —CH 2 COOH, —COOR 2a , or —CH 2 COOR 2a ; R 2a is C 1-2 alkyl, where the alkyl may be substituted with one to three of the same or different substituents selected from halogen atoms; R 3 is H, C 1-6 alkyl, where the alkyl may be substituted with one to three of the same or different substituents selected from R 11 ; R 10 is F, Cl, CF 3 , or C 1-2 alkyl; R 11 is halogen atom, hydroxy, or cyano; W is selected from: W 2a is H, halogen atom, cyano, C 1-2 alkyl, or C 3-5 cycloalkyl, or a pharmaceutically acceptable salt or ester thereof.

  本发明涉及化合物I式：其中：R1为H，—NHCOOR1a，C5-6环烷基或苯基；其中环烷基和苯基各自独立地可用R10中的一到三个相同或不同的取代基取代；R1a为C1-3烷基，可用F和Cl中的一到三个相同或不同的取代基取代；R2为H，—COOH，—CH2COOH，—COOR2a或—CH2COOR2a；其中R2a为C1-2烷基，该烷基可用卤素原子中的一到三个相同或不同的取代基取代；R3为H，C1-6烷基，该烷基可用R11中的一到三个相同或不同的取代基取代；R10为F，Cl，CF3或C1-2烷基；R11为卤素原子，羟基或氰基；W选自：W2为H，卤素原子，氰基，C1-2烷基或C3-5环烷基，或其药学上可接受的盐或酯。
• INHIBITORS OF BRUTON'S TYROSINE KINASE
  申请人：Pharmacyclics, Inc.

  公开号：US20150094319A1

  公开（公告）日：2015-04-02

  Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

  本文披露了一些化合物，它们可以与布鲁顿酪氨酸激酶（Btk）形成共价键。还描述了Btk的不可逆抑制剂。此外，还描述了Btk的可逆抑制剂。还披露了包括这些化合物的药物组合物。披露了使用Btk抑制剂的方法，单独或与其他治疗剂联合使用，用于治疗自身免疫性疾病或病况、异种免疫性疾病或病况、包括淋巴瘤在内的癌症和炎症性疾病或病况。